STEVEN LESTER: Open Payments
NPI 1902688377 · RICHLANDS, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$870 in 44 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $233 · 2025 $870
Food & beverage: $870
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 9 | $177 |
| Vanda Pharmaceuticals Inc. | 2 | $150 |
| ABBVIE INC. | 13 | $135 |
| Otsuka America Pharmaceutical, Inc. | 6 | $132 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $105 |
| Janssen Pharmaceuticals, Inc | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Exact Sciences Corporation | 1 | $23 |
| Novo Nordisk Inc | 1 | $20 |
Products named: INGREZZA, REXULTI, FANAPT, VRAYLAR, CAPLYTA, SPRAVATO, TRINTELLIX, INJECTAFER.
Industry payments across VA — which companies pay providers there.
